ADELPHI, Md. (Reuters) - A highly anticipated lupus treatment from Human Genome Sciences Inc moved closer to the U.S. market on Tuesday with an endorsement from a government advisory panel.
Benlysta could become the first medicine in a half-century to win approval for fighting the debilitating and potentially fatal autoimmune disease. Annual global sales are forecast at $2.2 billion by 2014, according to Thomson Reuters.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
